Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Harrow Inc HROW

Healthcare Drug Manufacturers - Specialty & Generic
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Announces Nashville Expansion

Business Wire September 25, 2024

Harrow to Present at Three Investor Conferences in September in New York

Business Wire September 3, 2024

Harrow Announces Second Quarter 2024 Financial Results

Business Wire August 7, 2024

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Business Wire July 25, 2024

Harrow to Attend 2024 ASRS Annual Meeting

Business Wire July 12, 2024

Harrow Enters into 340B Prime Vendor Program Contract with Apexus(TM) for IHEEZO® and Other Key Harrow Products

Business Wire July 9, 2024

Harrow Provides TRIESENCE® Relaunch Update

Business Wire June 20, 2024

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Business Wire June 6, 2024

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

Business Wire June 5, 2024

Harrow to Present at Two Investor Conferences in May

Business Wire May 15, 2024

Harrow Announces First Quarter 2024 Financial Results

Business Wire May 13, 2024

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

Business Wire May 13, 2024

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

Business Wire April 25, 2024

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Business Wire April 2, 2024

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

Business Wire March 19, 2024

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

Business Wire March 5, 2024

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

Business Wire February 15, 2024

Harrow Announces New Appointments to its Board of Directors

Business Wire January 29, 2024

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Business Wire January 11, 2024

Melt Pharmaceuticals Provides Corporate Update

Business Wire January 3, 2024

Podcasts